CClinicalTrials.gg
Sign In
CompletedNCT01958411Updated Oct 9, 2013

Correlation Between NAFLD, Epicardial Adipose Tissue and Vascular Inflammation Measured by Positron Emission Tomography (PET) With 18F-fluoro-deoxyglucose (FDG)

An observational study in Atherosclerosis and Non-alcoholic Fatty Liver Disease, sponsored by Korea University. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-10-09.

Sponsored by Korea University · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
340
Ages
20 Years to 80 Years
Sex
All
01

Study summary

  • Vascular inflammation is a key factor in both the pathogenesis and outcome of atherosclerosis. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a promising tool for identifying and quantifying vascular inflammation within atherosclerotic plaques.
  • Non-alcoholic fatty liver disease (NAFLD) is closely associated with many cardiometabolic risk factors. NAFLD can be detected by measuring liver fat accumulation using computed tomography (CT).
  • Also epicardial adipose tissue (EAT) volume as determined by computed tomography (CT) is an independent marker of cardiovascular events in the general population.
  • Therefore, the purpose of this investigators study is to compare the NAFLD severity and EAT volume with FDG uptake measured by PET/CT.
02

Conditions studied

  • Atherosclerosis
  • Non-alcoholic Fatty Liver Disease
03

In context

Liver Diseases

2,080 studies on the registry are indexed under Liver Diseases; 389 are open to participants now.

This study's enrollment of 340 is above the median of 167 across 681 observational studies indexed under Liver Diseases.

Browse Liver Diseases studies →

Lead sponsor

Korea University is the lead sponsor of 64 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Healthy participants who underwent a medical health check in the health promotion center in Korea Guro University

Inclusion criteria

  • Healthy patients for visiting routine medical check in our clinic

Exclusion criteria

Exclusion Criteria:

  • History of cardiovascular disease (myocardial infarction, unstable angina, stroke, or cardiovascular revascularization)
  • Diabetes
  • Stage 2 hypertension (resting blood pressure, ≥ 160/100 mmHg)
  • Malignancy
  • Severe renal or hepatic disease
  • Subjects taking medications that might affect inflammation such as nonsteroidal antiinflammatory drug and statin
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
340 participants (actual)
Patient registry
No

Groups and cohorts

  • 18FDG-PET/CT
06

What researchers measure

Primary outcomes

  1. Correlation between vascular inflammatory status measured by 18FDG PET and NAFLD measured by un-enhanced CT

    Time frame: 12 weeks

  2. Correlation between vascular inflammatory status measured by 18FDG PET and epicardial adipose tissue measured by CT

    Time frame: 12 weeks

Secondary outcomes

  1. The relationship of NAFLD with carotid intima media thickness

    Time frame: 12 weeks

  2. The relationship of epicardial adipose tissue volume with carotid intima media thickness

    Time frame: 12 weeks

07

Study locations

1 site
  • Korea University Guro Hospital
    Seoul, Korea, Republic of
08

References and documents

Publications

  • Lee HJ, Lee CH, Kim S, Hwang SY, Hong HC, Choi HY, Chung HS, Yoo HJ, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM. Association between vascular inflammation and non-alcoholic fatty liver disease: Analysis by 18F-fluorodeoxyglucose positron emission tomography. Metabolism. 2017 Feb;67:72-79. doi: 10.1016/j.metabol.2016.11.004. Epub 2016 Nov 6. PubMed 28081780 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 9, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01958411
Lead sponsor
Korea University
Responsible party
K. M. Choi (Professor, Korea University) — Principal investigator
First posted
Oct 9, 2013
Start date
Dec 2008
Primary completion
Mar 2011
Last update
Oct 9, 2013

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Liver Diseases→

Other studies from this sponsor

Korea University

Start the discussion